Physician profile
Jala Redmon
NPI 1407432305
$5,998.12
in general payments reported to CMS, 2019-2025
37 companies · $1,771 in 2025
The $1,771 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $228 · 2022: $1,249 · 2023: $1,368 · 2024: $1,381 · 2025: $1,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,520.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $795.37 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $628.06 | 2022-2025 | |
| Glaxosmithkline, LLC. | $581.74 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $574.71 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $505.73 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $398.89 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $359.51 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $209.67 | 2021-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $181.13 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $172.04 | 2022-2025 | Quviviq, Quviviq |
| Lilly USA, LLC | $170.45 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $151.00 | 2022-2025 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.25 | 2022-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $104.95 | 2024-2025 | |
| Corium, LLC | $98.49 | 2023-2025 | Azstarys |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jala Redmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.